MLTX

Latest SEC Filings & News for MLTX

2 most recent filings and news items mentioning MLTX. Updated every 60 seconds.

Get this data via API — free tier: 10,000 calls/day

curl "https://api.brieftape.com/v1/tickers/MLTX/news?limit=20"

Pull MLTX filings straight into your trading bot, model, or app.

Get an API key — free tier: 10,000 calls/day

RegulatoryJul 27, 2026Neutral

ML-007C-MA Phase 2 trial results released

MapLight Therapeutics reported topline data from its Phase 2 ZEPHYR trial evaluating its schizophrenia candidate ML-007C-MA. The data release is critical for the company's clinical development plans and potential market position in the psychiatric disorders treatment space.

View filing at SEC.gov →

RegulatoryJun 22, 2026Positive

MoonLake Reports Strong Week 52 Sonelokimab Results in Phase 3 HS Trials

MoonLake's sonelokimab achieved 67% HiSCR75 response rate and 26% inflammatory remission at Week 52 in hidradenitis suppurativa trials, with BLA submission expected September 2026. The results position the drug as potentially best-in-class compared to competing agents, supporting

View filing at SEC.gov →

AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.